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ABSTRACT Ebola virus (EBOV) protein VP35 inhibits production of interferon alpha/
beta (IFN) by blocking RIG-I-like receptor signaling pathways, thereby promoting vi-
rus replication and pathogenesis. A high-throughput screening assay, developed to
identify compounds that either inhibit or bypass VP35 IFN-antagonist function, iden-
tiﬁed ﬁve DNA intercalators as reproducible hits from a library of bioactive com-
pounds. Four, including doxorubicin and daunorubicin, are anthracycline antibiotics
that inhibit topoisomerase II and are used clinically as chemotherapeutic drugs.
These compounds were demonstrated to induce IFN responses in an ATM kinase-
dependent manner and to also trigger the DNA-sensing cGAS-STING pathway of IFN
induction. These compounds also suppress EBOV replication in vitro and induce IFN
in the presence of IFN-antagonist proteins from multiple negative-sense RNA viruses.
These ﬁndings provide new insights into signaling pathways activated by important
chemotherapy drugs and identify a novel therapeutic approach for IFN induction
that may be exploited to inhibit RNA virus replication.
IMPORTANCE Ebola virus and other emerging RNA viruses are signiﬁcant but un-
predictable public health threats. Therapeutic approaches with broad-spectrum ac-
tivity could provide an attractive response to such infections. We describe a novel
assay that can identify small molecules that overcome Ebola virus-encoded innate
immune evasion mechanisms. This assay identiﬁed as hits cancer chemotherapeutic
drugs, including doxorubicin. Follow-up studies provide new insight into how doxo-
rubicin induces interferon (IFN) responses, revealing activation of both the DNA
damage response kinase ATM and the DNA sensor cGAS and its partner signaling
protein STING. The studies further demonstrate that the ATM and cGAS-STING path-
ways of IFN induction are a point of vulnerability not only for Ebola virus but for
other RNA viruses as well, because viral innate immune antagonists consistently fail
to block these signals. These studies thereby deﬁne a novel avenue for therapeutic
intervention against emerging RNA viruses.
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Emerging RNA viruses are an ongoing but unpredictable threat to public health. Apotential answer to this threat would be a broad-spectrum therapeutic approach
targeting host pathways in a manner that would inhibit the diverse virus families that
are likely to cause outbreaks in the human population. Ebola virus (EBOV), a member
of the family Filoviridae, represents one such threat. EBOV has repeatedly been asso-
ciated with outbreaks of highly lethal human disease (1). The need for antiﬁloviral
therapies is highlighted by the EBOV outbreak in West Africa that caused more than
28,000 infections and 11,000 deaths (2). One potential avenue for therapeutic inter-
vention would be to target the innate immune evasion functions of EBOV and other
emerging RNA viruses. Filoviruses inhibit type I interferon (IFN) responses at multiple
levels (3–13). One major mechanism of EBOV IFN suppression is carried out by the VP35
protein, which inhibits signaling by the RIG-I-like receptors (RLR), RIG-I and MDA5 (11,
14, 15). Suppression of RLR signaling not only prevents IFN production but can also
block the induction of a subset of antiviral genes that can be expressed as a direct result
of RLR signaling and independently of IFN production. Further, for EBOV, VP35 inhibi-
tion of RLR signaling suppresses dendritic cell (DC) maturation, likely contributing to
suppression of adaptive immune responses (15, 16). That the IFN-antagonist function of
VP35 represents a potential therapeutic approach for Ebola virus disease (EVD) is
suggested by the fact that recombinant EBOVs engineered to lack VP35 IFN-antagonist
function exhibit severe attenuation in cell culture and in vivo (12, 17, 18).
Numerous RNA viruses target RLR pathways and other aspects of the IFN response
(as reviewed in references 19 and 20). Identiﬁcation of an IFN-inducing pathway that
bypasses blocks imposed by EBOV and other RNA viruses could serve as a means to
generally suppress RNA virus replication. Candidate pathways include cellular DNA-
sensing pathways that lead to IFN gene expression; viruses that lack a DNA genome
and do not produce DNA products of replication may not have evolved mechanisms
to suppress the DNA-induced responses. Among DNA-sensing mechanisms, the
kinase ATM, which is activated in response to DNA breaks, has been identiﬁed as
promoting IFN production, although relevant downstream signaling events that
lead to IFN production remain incompletely deﬁned (21–26). Another particularly
well-characterized DNA sensing pathway is the cGAS-STING pathway, in which cyto-
plasmic DNA binds and activates the enzyme cGAS, triggering its generation of the
cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP) (27, 28). CDN activates signaling
through STING to trigger IFN production (29–31). The cGAS-STING pathway has also
been implicated in triggering IFN production in response to DNA damage (22).
Anthracycline antibiotics are a class of compounds which includes commonly used
cancer chemotherapy drugs such as doxorubicin, which, although highly effective in
killing tumor cells, is limited in its usage due to its cardiotoxicity (32). These compounds
intercalate DNA, inhibit type II topoisomerase, and trigger the DNA damage response
(33, 34). One interesting but relatively understudied effect of these compounds on cells
is induction of IFN responses; induction of such responses has been proposed to
modulate immune responses that may inﬂuence the antitumor effects of doxorubicin
(35, 36).
Here, we developed and optimized a high-throughput screening (HTS) assay in a
384-well format with the initial goal of identifying compounds that induce IFN in the
presence of EBOV VP35 protein. A screen of 2,080 bioactive compounds identiﬁed
DNA-intercalating chemotherapeutic agents such as doxorubicin and daunorubicin as
reproducible activators of the IFN- promoter in the presence of VP35. These drugs are
DNA topoisomerase II poisons that intercalate DNA (37). We demonstrate that these
drugs can activate the IFN- promoter via either the DNA damage response-associated
kinase ATM or the cGAS-STING pathway, that activation of the ATM pathway requires
the presence of DNA topoisomerase II, and that VP35 blocks neither pathway. The
compounds are further demonstrated to suppress EBOV replication and to activate an
IFN response in the presence of IFN antagonists from several different RNA viruses.
These observations identify new host pathways that are activated by anthracycline
chemotherapeutic drugs, deﬁne mechanisms by which these pathways are activated,
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and suggest that the DNA damage response and DNA-sensing pathways could be
exploited to treat infections by EBOV and other RNA viruses.
RESULTS
An HTS assay to identify small-molecule inhibitors of VP35. A 293T-based stable
cell line with a ﬁreﬂy luciferase reporter gene under the control of the IFN- promoter
(293T-FF) was transduced with a lentivirus that expresses from a single mRNA both
VP35 and green ﬂuorescent protein (GFP) (15). This yielded the cell line VP35-FF. In this
cell line, an internal ribosomal entry site separates the open reading frames for VP35
and GFP such that the two proteins are translated as distinct polypeptides. Alterna-
tively, the reporter cell line was transduced with an “empty-vector” lentivirus that
expresses GFP alone (control-FF). Clonal VP35-FF and control-FF cell lines were ob-
tained by sorting for GFP expression (see Fig. S1A in the supplemental material). Upon
infection with Sendai virus (SeV), a known activator of RLR signaling and of the IFN-
promoter, a strong upregulation of luciferase expression was detected in the control-FF
cells, whereas the VP35-FF cells exhibited little response to infection, reﬂecting VP35
inhibition of RLR signaling and IFN- promoter activation (Fig. S1B). Examination of
endogenous mRNA levels for IFN- and interferon stimulated gene 54 (ISG54) yielded
parallel results (Fig. S1C and D), demonstrating that the reporter gene accurately
reﬂects the status of the endogenous IFN response.
For an HTS screen, it was desirable to identify a positive-control compound that
would induce an IFN response in the presence of VP35. However, no small-molecule
inhibitor of VP35 IFN-antagonist function has been described. We assessed the FDA-
approved chemotherapeutic drug doxorubicin, which has been reported to induce an
IFN response and to stimulate IFN regulatory factor 3 (IRF-3) phosphorylation by an
incompletely deﬁned mechanism (38, 39). Doxorubicin activated the IFN- promoter in
the presence or absence of VP35 (Fig. S1B). Doxorubicin also stimulated an endogenous
IFN response in either reporter cell line as indicated by upregulation of IFN- and ISG54
mRNAs (Fig. S1C and D). As doxorubicin induced IFN in the presence or absence of VP35
and IFN induction occurred in the absence of an RLR activator such as SeV, IFN
induction by doxorubicin is likely through a signaling pathway that is not blocked by
VP35.
An HTS assay based on the VP35-FF cell line was developed to allow identiﬁcation
of additional small molecules that induce an IFN response in the presence of VP35
(Fig. 1A). Brieﬂy, VP35-FF cells were plated in 384-well plates, allowed to rest for 2 h, and
infected with SeV in the presence of either diluent (0.1% dimethyl sulfoxide [DMSO]) or
3 M doxorubicin. Immediately afterward, compounds were added via pin tool transfer.
Twenty hours postaddition, luciferase activity was measured. A representative pilot
study compared VP35-FF cells that were infected with SeV and treated with DMSO
(SeV  DMSO) to the same cells infected with SeV and treated with 3 M doxorubicin
(SeV doxorubicin). Comparison of the two conditions yielded an 83-fold induction by
doxorubicin over the DMSO control and a Z factor of 0.7 (Fig. S1E). A Z factor value of
0.5 indicates a high-quality screening assay (40). To establish that inhibition of VP35
can result in activation of IFN- promoter by SeV in the VP35-FF cells, we utilized
previously described VP35 small interfering RNAs (siRNAs) si349 and si219 (41). VP35-FF
cells that were transfected with the siRNAs to VP35 mRNA had reduced VP35 expression
levels compared to a scrambled siRNA (Fig. S1F). Following SeV infection, little IFN-
promoter activation was observed in the scrambled siRNA-treated cells, but IFN-
responses were stimulated by SeV infection upon VP35 knockdown (Fig. S1F).
Doxorubicin-mediated activation of IFN- promoter was not impaired by VP35 knock-
down.
Using the optimized conditions for the 384-well format, we screened a library of
2,080 bioactive compounds (Fig. 1B). The eight library plates were each screened in
duplicate, and the Z factor for each plate was 0.5 (Fig. 1C). The Z scores, which
indicate how many standard deviations a given value is from the mean, were calculated
for each compound, and those compounds with Z scores of 5 in both replicates were
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classiﬁed as hits. This resulted in 5 hits. Perhaps unsurprisingly, the hits included
doxorubicin. Strikingly, three other hits were daunorubicin, epirubicin, and aklavine
hydrochloride, all anthracycline antibiotics that are structurally very similar to doxoru-
bicin. Doxorubicin, daunorubicin, and epirubicin are used as chemotherapeutic drugs
for cancer (42, 43). The last hit was aminacrine (9-aminoacridine), a ﬂuorescent dye used
clinically as a topical antiseptic and experimentally as a mutagen due to its interaction
with DNA (44) (Fig. 1D).
Doxorubicin and daunorubicin stimulate production of IFN-/. We asked how
anthracyclines stimulate an IFN response and why this stimulation is not blocked by
VP35, choosing doxorubicin and daunorubicin for this analysis. First, the doses required
for IFN- promoter activation and for cytotoxicity were determined in both VP35-FF
(Fig. 2A and B) and control-FF (Fig. 2C and D) cells in the absence or presence of SeV
infection. Both compounds were toxic to cells at higher concentrations (25 to 50 M),
consistent with their use as cancer drugs. However, each activated the IFN- promoter
at concentrations far below cytotoxic levels, with as little as 780 nM inducing luciferase
expression and with peak stimulation at 3 M in either the VP35-FF cells (Fig. 2A and
B) or the control-FF cells (Fig. 2C and D). To conﬁrm that neither doxorubicin nor
daunorubicin nonspeciﬁcally enhances luciferase activity, cells transfected with a re-
VP35-FF cells Plate in 384 well plate
25K cells/20μl/well
Addition of Sendai Virus
 (SeV, 10μl) or SeV with
 Doxorubicin (3μM, 10μl)
Compound transfer































































FIG 1 Establishing a high-throughput screening (HTS) assay to identify inhibitors of VP35. (A) Schematic for
high-throughput screening assay of VP35 function. Stable VP35 cells were dispensed in 384-well plates using an
automated dispenser. Two hours later, cells were treated with SeV (negative control) or SeV plus doxorubicin
(positive control). Compound addition was done via pin tool transfer. Twenty hours posttreatment, a luciferase
assay was performed. (B) Results of HTS. A total of 2,080 bioactive compounds were screened (8 screening plates).
Each screening plate was run in duplicate (indicated by A or B). Data points indicate relative luciferase units (RLU)
for each sample. Controls were as described for panel A. The overall Z factor for the screen was greater than 0.5,
and the signal-to-background ratio (S/B) was greater than 100. (C) Z values for each 384-well plate in the pilot
screen are plotted. (D) The 5 hits identiﬁed by the pilot screen that had a Z score greater than 5 in both replicates
are listed along with the average Z score for the two replicates. See also Fig. S1 in the supplemental material.
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porter plasmid from which ﬁreﬂy luciferase is constitutively expressed were treated
with different doses of each drug. No signiﬁcant stimulation was observed, demon-
strating speciﬁcity toward the IFN- promoter reporter gene (Fig. 2E and F). To
determine whether the IFN- induction occurs in other cell types, we transiently
transfected A549 cells with an IFN-–luciferase reporter gene and with empty vector or
VP35 expression plasmid and treated them with different doses of doxorubicin or
daunorubicin. Each drug induced reporter gene expression at noncytotoxic doses in the


























































































































































































































FIG 2 IFN induction and cytotoxicity of doxorubicin and daunorubicin in reporter cell lines. (A to D) (A and B) Dose
response in VP35 cells for activation of the IFN- reporter luciferase reporter gene (bars) and for cytotoxicity (triangles) of
doxorubicin (A) or daunorubicin (B). (C and D) Dose response in control-FF cells for activation of the IFN- reporter
luciferase reporter gene by doxorubicin (C) and daunorubicin (D). (E and F) The effect of doxorubicin (E) and daunorubicin
(F) on expression of a constitutively expressed ﬁreﬂy luciferase gene. Percent luciferase activity is relative to that with no
drug treatment. Data represent means  standard deviations and are representative of three independent experiments.
RLU, relative luciferase units.
Topoisomerase II Inhibitors Induce IFN Responses ®















endogenous IFN- and ISG54 mRNAs regardless of whether VP35 was expressed
(Fig. 3C and D).
Doxorubicin and daunorubicin induce IFN by an ATM-dependent mechanism.
Doxorubicin has pleiotropic effects on cells. Among its activities, it is a topoisomerase
II poison that intercalates into DNA, resulting in double-strand DNA breaks (DSB) (24,
45). Ataxia-telangiectasia mutated (ATM), a member of the phosphoinositide 3-kinase-
like family of serine/threonine protein kinases, is activated in response to DNA DSB (25,
46–48). ATM has also been linked to stimulation of innate immune signaling pathways
(26, 49–52). This prompted us to examine the role of ATM in doxorubicin- and
daunorubicin-mediated activation of the IFN- promoter. We treated control-FF or
VP35–FF cells with an ATM kinase inhibitor (Ku55933) (53) or with mirin, an inhibitor of
the Mre11-Rad50-Nbs1 (MRN)-ATM pathway, which is essential for sensing and signal-
ing in response to double-strand DNA breaks. Mirin prevents MRN-dependent activa-
tion of ATM without affecting ATM protein kinase activity and inhibits Mre11-associated
exonuclease activity (54). Each inhibitor signiﬁcantly dampened, in the presence or
absence of VP35, the IFN- promoter activity induced by doxorubicin or daunorubicin
compared to DMSO treatment (Fig. 4A). To further implicate the ATM pathway in the
response to doxorubicin, short hairpin RNA (shRNA) knockdown of ATM was performed.
Relative to a scrambled shRNA, targeting ATM decreased the doxorubicin-mediated IFN
induction in control-FF and VP35-FF cells relative to mock-treated controls (Fig. 4B). In















































































































































IFN-β mRNA ISG54 mRNA
FIG 3 Induction of an IFN response by doxorubicin and daunorubicin is not cell type speciﬁc. Dose response for activation
of the IFN- reporter gene (bars) and for cytotoxicity (triangles) of doxorubicin (A) or daunorubicin (B) in A549 cells
transfected with empty vector (vector) or VP35. Reverse transcription-quantitative polymerase chain reaction (qRT-PCR) was
performed for endogenous IFN- (C) or ISG54 (D) mRNA levels in A549 cells transfected with empty vector (vector) or VP35
and treated with doxorubicin. The RNA was isolated 12 h after treatment with the indicated concentrations of drug, and levels
were normalized to levels of -actin mRNA. Data represent means  standard deviations and are representative of three
independent experiments.
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FIG 4 An ATM-dependent IFN response that is not blocked by VP35 is stimulated by doxorubicin and daunorubicin. (A) An
IFN- promoter assay was performed as described above except that cells (control or VP35) were treated with DMSO, ATM
kinase inhibitor Ku55933 (10 M), or mirin (10 M) for 2 h before doxorubicin (1 M) or daunorubicin (1 M) treatment or
SeV infection. ****, P value  0.0001 (one-way analysis of variance followed by Tukey’s test). (B) IFN- promoter reporter gene
assays were performed as described above except that cells were transfected with scrambled shRNA (sh Scrm.) or ATM-speciﬁc
shRNA (sh ATM) plasmids. ****, P value  0.0001 (one-way analysis of variance followed by Tukey’s test). A Western blot for
ATM and VP35 is shown in the inset. M, mock treated (medium  DMSO); S, SeV infected; D, doxorubicin (1 M) treated. (C)
Phospho-ATM (S1981), phospho-p53 (S15), total ATM, total p53, and VP35 levels were assessed by Western blotting in
HEK293T cells transfected with empty vector or VP35 and mock treated (mock), treated with doxorubicin (Doxo), or infected
with SeV (SeV) at 4 h posttreatment. -Tubulin served as a loading control. (D) Phospho-IRF-3 (p-IRF-3) and total IRF-3 (IRF-3)
levels were assessed in HEK293T cells transfected with FLAG-IRF-3 plasmid and either empty vector (vector) or VP35 plasmid.
The cells were either mock treated or treated with doxorubicin or infected with SeV for 8 h. -Tubulin served as a loading
control. Total IRF-3 levels were assessed by using anti-FLAG, p-IRF-3 levels were assessed by using anti-p-IRF-3 (Ser396), and
VP35 levels were assessed by using anti-VP35 antibodies. (E) NF-B ﬁreﬂy luciferase reporter gene activity in mock- or
VP35-transfected cells that were mock treated (medium  DMSO), treated with doxorubicin, or infected with SeV in the
presence or absence of ATM kinase inhibitor Ku55933. Cells treated with 50 ng/ml of TNF- for 2 h served as a known NF-B
activation control. Fold induction is relative to the mock-treated, vector control. Data represent means  standard deviations
(Continued on next page)
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fected SeV-mediated induction of IFN- promoter activity in control-FF cells (Fig. 4A
and B).
Activation of ATM results in its phosphorylation and the phosphorylation of down-
stream targets, including p53. To further establish that the ATM pathway is active upon
doxorubicin treatment, we examined the phosphorylation status of ATM and p53. The
phosphorylation of ATM serine 1981 and of p53 serine 15 was assessed after 6 h of
treatment with doxorubicin. SeV infection was included as a control. The drug but not
SeV resulted in phosphorylation of ATM and p53 in the presence or absence of VP35
(Fig. 4C). Both IRF-3 and NF-B are transcription factors that contribute to induction of
the IFN- promoter. Doxorubicin treatment also resulted in Ser396 phosphorylation of
IRF-3, consistent with its activation. In contrast to the inhibition seen with SeV infection,
VP35 did not prevent doxorubicin-induced IRF-3 phosphorylation (Fig. 4D). Further,
doxorubicin activated NF-B-directed gene expression, as assessed by reporter gene
assay, and this was impaired by the ATM kinase inhibitor but not by VP35. This was in
contrast to the case when SeV or tumor necrosis factor alpha (TNF-) was used as an
NF-B activator, where ATM inhibition did not affect induction (Fig. 4E). Cumulatively,
these data suggest that doxorubicin and related compounds induce IFN responses, at
least in part, via an ATM-dependent pathway and that VP35 expression does not block
this pathway.
Doxorubicin targets topoisomerase II (Top2A) and generates stabilized DNA-
topoisomerase II covalent complexes (33). Decreasing levels of Top2A render cells
resistant to killing by doxorubicin (34, 55). To examine whether decreased Top2A levels
inﬂuence activation of the IFN- promoter, small interfering RNA was used to decrease
Top2A expression. Downregulation of Top2A expression reduced IFN- promoter
activation by doxorubicin in both the presence and the absence of VP35 but did not
have any effect on SeV-mediated activation of IFN (Fig. 4F). Cumulatively, these data are
consistent with a model whereby doxorubicin inhibition of Top2A activates ATM, which
leads to IFN induction.
The cGAS-STING axis can also contribute to doxorubicin-mediated activation of
interferon responses. DNA damage or infection may lead to generation of cytosolic
DNA (cDNA) that can trigger IFN induction (56, 57). The endoplasmic-reticulum-resident
protein stimulator of interferon genes (STING) is required for the initiation of signaling
leading to IFN production upon detection of cytosolic DNA and also serves as a direct
receptor for the detection of DNA (29, 58). cGAS (cyclic GMP-AMP synthase) is an
enzyme that recognizes DNA in the cytoplasm and generates a unique cGAMP isomer,
with one 2=-5= phosphodiester bond and one 3=-5= phosphodiester bond, that binds
and activates STING (59). Interestingly, the cGAS-STING pathway has been implicated in
induction of IFN by cellular DNA damage (22). cGAS and STING were not detectable by
Western blotting in the 293T cell-based control-FF or VP35-FF cell lines (Fig. S2A), which
is consistent with a previous report that 293T cells lack cGAS and STING (60). Therefore,
to address the potential role of these proteins to signal in response to doxorubicin,
293T-based reporter cell lines were stably transduced with lentiviruses that express
wild-type human STING (STING-FF cells) (29, 61–63).
To validate the STING cell lines, empty vector or VP35 was transfected along with
expression plasmids for wild-type cGAS (cGAS-wt), a cGAS nucleotidyltransferase
G212A/S213A mutant (cGAS-NTase), or a cGAS DNA binding mutant C396A/C397A
(cGAS-DBM). cGAS-NTM has mutations in the active site of cGAS and abolishes pro-
duction of cGAMPs by cGAS (64, 65). cGAS-DBM was generated by mutating two
cysteine residues of the zinc-binding site so as to abolish DNA-induced NTase activity
(65, 66). The following day, the cells were mock treated, infected with SeV, or treated
FIG 4 Legend (Continued)
and are representative of three independent experiments. **, P value  0.01. (F) IFN- reporter gene assays were performed
as described above in control cells or VP35 cells but in the presence of scrambled siRNA (scrm.) or Top2A-speciﬁc siRNA
(Top2a). ***, P value  0.001 (one-way analysis of variance followed by Tukey’s test). The inset shows Western blotting assays
to detect Top2A and -tubulin. M, mock treated; D, doxorubicin treated; S, SeV infected.
Luthra et al. ®















with doxorubicin, and 20 h later, luciferase activity was measured (Fig. 5A). Each cell line
responded comparably to SeV infection, regardless of the form of cGAS expressed. In
the cells lacking cGAS but possessing STING, a modest upregulation of the IFN-
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FIG 5 cGAS and STING enhance IFN induction by doxorubicin. (A) IFN- reporter gene assays were performed as described
above in control cells or cell lines with stable expression of STING. These were transfected with empty vector, cGAS-wt, NTase
mutant cGAS (cGAS-NTM), or DNA binding cGAS mutant (cGAS-DBM). Some cells were also transfected with VP35 plasmid, as
indicated. The next day, cells were mock treated, treated with doxorubicin (Doxo), or infected with SeV. Twenty hours later,
reporter gene activity was measured. The Western blot indicates expression of STING, cGAS, VP35, and -tubulin as a loading
control. (B and C) IFN- reporter control cells or cells stably expressing STING and wt-cGAS were transduced with empty vector
or VP35-expressing lentiviruses. Three days later, cells were pretreated with ATM kinase inhibitor Ku55933 (10 M) for 2 h (B)
or transfected with scrambled short hairpin RNA (sh scrnm.) or ATM-speciﬁc short hairpin RNA plasmid (sh ATM) to knock
down ATM expression (C) and mock treated (medium  DMSO), treated with doxorubicin (Doxo, 3 M), induced with
c-di-GMP (20 g), or infected with SeV. Twenty hours later, IFN- reporter activation was measured by luciferase assay. The
Western blots show expression of STING, cGAS, ATM, VP35, and -tubulin. ****, P value  0.0001 (one-way analysis of variance
followed by Tukey’s test). Error bars represent means  standard deviations, and values are representative of three
independent experiments. See also Fig. S2 and S3 in the supplemental material.
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substantially enhanced by expression of cGAS-wt when STING was present. In neither
the cGAS-NTM nor the cGAS-DBM cells did doxorubicin result in the enhanced IFN-
promoter activation (Fig. 5A). This suggests that the enhanced IFN- response to
doxorubicin requires cGAS with an intact DNA-sensing capacity and STING and that
STING is responding to cGAS-generated CDN. This provides evidence that doxorubicin
can activate the cGAS-STING DNA-sensing pathway to induce IFN- expression. In these
experiments, VP35 expression inhibited the SeV-mediated but not the doxorubicin-
mediated activation of the IFN- promoter, indicating that VP35 is unable to block
doxorubicin-induced signaling through cGAS and STING.
To determine whether ATM signaling contributes to the cGAS-STING response, a
293T-based stable reporter cell line expressing cGAS-wt and STING was generated
(cGAS-wtSTING-FF cells). The control or the STINGcGAS-wt reporter cell line was
then transduced with either an empty-vector lentivirus or a VP35-expressing lentivirus.
Three days after transduction, the cells were mock treated or treated for 2 h with ATM
kinase inhibitor (Fig. 5B). Alternatively, the cells were transfected with expression
plasmids that produce either a scrambled shRNA or an ATM-speciﬁc shRNA (Fig. 5C).
Two days later, these cells were then mock treated, infected with SeV, treated with
doxorubicin, or transfected with cyclic di-GMP (c-di-GMP), a CDN that can activate
signaling through STING. Twenty hours later, luciferase activity was determined. The
c-di-GMP treatment stimulated the IFN- promoter in cGAS-wtSTING-FF cells relative
to control cells lacking STING and cGAS (Fig. 5B and C), demonstrating that STING
signaling is intact. Expression of STING and cGAS once again signiﬁcantly enhanced
doxorubicin-mediated IFN- promoter activation (Fig. 5B and C). The presence of ATM
kinase inhibitor or ATM shRNA dampened but did not abolish this response (Fig. 5B and
C). This suggests that the ATM pathway contributes to the response in the presence of
STING and cGAS. As seen previously, VP35 inhibited the SeV-induced response. How-
ever, VP35 did not inhibit the doxorubicin-induced response, the cyclic-di-GMP-induced
response, or the residual IFN response detected in the presence of ATM inhibitor or
ATM shRNA (Fig. 5B and C). This reinforces the view that ATM- and cGAS/STING-
dependent IFN responses are insensitive to inhibition by VP35.
In humans, loss-of-function mutations in ATM result in ataxia telangiectasia (AT)
(67–69). Comparison of ﬁbroblasts from healthy subjects with ATM patient-derived
ﬁbroblasts demonstrated a constitutive elevation of IFN- and ISG54 mRNAs in the
absence of ATM, even when VP35 was introduced via a lentiviral vector (Fig. S2B). This
is consistent with previous reports that sustained ATM deﬁciency upregulates an IFN
response in AT cells via the STING pathway due to accumulation of damaged DNA in
the cytoplasm (22). Interestingly, despite the fact that our transient knockdown of ATM
decreased IFN responses to doxorubicin in the 293T cell system, treatment of AT
ﬁbroblasts with doxorubicin still yielded a strong IFN- response compared to healthy
control ﬁbroblasts (Fig. S2C and D). The c-di-GMP treatment was used as a control for
STING-mediated induction of IFN in these cells, which indeed resulted in modest
activation of the IFN response. Notably, VP35 had no inhibitory effect on c-di-GMP- or
doxorubicin-mediated response in these cells. This demonstrates that doxorubicin can
induce an IFN response in the absence of ATM and that doxorubicin therefore can
induce IFN- by at least two distinct pathways, neither of which is impaired by VP35.
To conﬁrm IFN induction in cells that express endogenous cGAS and STING and that
have a responsive ATM signaling machinery, primary human monocyte-derived den-
dritic cells (MDDCs) were examined (Fig. S2E and F) (70). MDDCs were transduced with
control or VP35 lentiviruses and 72 h later infected with SeV or treated with either
doxorubicin or c-di-GMP. RNA was then isolated to determine IFN- (Fig. S2E) and ISG54
(Fig. S2F) mRNA levels. Again, doxorubicin upregulated the IFN response in either the
presence or the absence of VP35.
Because cGAS detects DNA (29) and because DNA damage can result in accumula-
tion of single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) species in the
cytoplasm (22), we asked whether doxorubicin treatment leads to colocalization of DNA
and cGAS. We performed colocalization studies with ssDNA and cGAS. Indeed, ssDNA
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levels increased upon doxorubicin treatment, and this ssDNA colocalized with cGAS in
both the nucleus and the cytoplasm (Fig. S3A and B). This suggests that doxorubicin-
mediated DNA damage results in production of ssDNA that may directly activate cGAS.
To further evaluate whether a DNA signal is responsible for the doxorubicin-
stimulated IFN response, we overexpressed Trex1, a 3= exonuclease that degrades the
single- and double-stranded DNA in the cytoplasm and that can prevent activation of
STING (57, 71, 72). Overexpression of Trex1 abrogated activation of IFN by doxorubicin
and by exogenously delivered immunostimulatory DNA (ISD) mediated in the presence
of cGAS-STING (Fig. S3C). As a control, we also overexpressed a Trex1 dominant mutant,
D18N, that lacks the ability to degrade dsDNA and is associated with autoimmune
disorders (71, 73, 74). Expression of the D18N mutant enhanced IFN response to
doxorubicin above that seen in the absence of the mutant, suggesting that doxorubicin
treatment results in cytoplasmic DNA that can trigger activation of the cGAS-STING
pathway (Fig. S3C). Interestingly, in the control cells which lack cGAS and STING
expression, a basal level of IFN activation was detectable following doxorubicin treat-
ment but not following treatment with ISD, and this induction was not affected by
Trex1 expression. This further supports the view that doxorubicin activates interferon
through both STING-dependent and -independent pathways. It also suggests that the
STING-independent pathway does not require the generation of cytoplasmic DNA.
Doxorubicin inhibits Ebola virus infection in vitro. Because doxorubicin can
induce an IFN response in the presence of VP35, the antiviral activity of doxorubicin
toward EBOV was assessed following drug pretreatment and infection of A549 cells
(multiplicity of infection [MOI] of 2). Cell cytotoxicity was assessed in parallel on
uninfected cells by measuring ATP content. A 10 M concentration of doxorubicin















































































FIG 6 Effect of doxorubicin in vitro. (A) The toxicity of doxorubicin was evaluated in A549 cells using the CellTiter-Glo assay
at 48 h after treatment with the drug. (B) Titers of an Ebola virus that expresses GFP (EBOV) after infection at a multiplicity
of 2 of A549 cells in the presence of DMSO or doxorubicin (10 M) (Doxo). The cells were pretreated with doxorubicin prior
to infection for 1 h, and doxorubicin was added back to the medium after the infection. The error bars indicate the
standard deviations from three independent replicates. **, P value  0.01 (Student’s two-tailed t test). Data represent
means  standard deviations from two independent experiments (each performed in triplicate). (C and D) qRT-PCR for
endogenous IFN- (C) and ISG54 (D) mRNA levels normalized to -actin mRNA at indicated postinfection time points. The
error bars indicate the standard deviations from three independent replicates. ***, P value  0.001; ****, P value  0.0001
(Student’s two-tailed t test). hpi, hours postinfection.
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expressing GFP (EBOV-GFP) by 20-fold, to 5  104 PFU/ml from 1  106 PFU/ml at 48 h
(Fig. 6B). Consistent with its activation of IFN responses in the presence of VP35,
EBOV-GFP infection had no impact on doxorubicin-induced IFN- or ISG54 mRNAs in
infected cells (Fig. 6C and D). Overall, these results suggest that doxorubicin is capable
of stimulating an IFN response that has an anti-EBOV effect in vitro.
Doxorubicin bypasses the IFN antagonists of multiple negative-sense RNA
viruses. To determine whether doxorubicin can generally induce an IFN response by
mechanisms that bypass the inhibitory effects of negative-sense RNA virus-encoded IFN
antagonists, reporter assays were performed in the presence of EBOV VP35, Marburg
virus VP35, inﬂuenza A virus NS1, Nipah virus (NiV) V and W, or respiratory syncytial
virus (RSV) NS1 or NS2 proteins. Each protein was detectably expressed following
transfection (Fig. S4). Doxorubicin stimulated IFN- and ISG54 promoter activity in the
presence of each of these IFN antagonists, whereas activation by RIG-I-activating SeV
was inhibited by each of them (Fig. 7A and B). The presence of cGAS and STING
dramatically enhanced the IFN- promoter activation by doxorubicin in the presence of
all antagonists relative to the control cells lacking cGAS and STING (Fig. 7E and F). Also,
consistent with an inability of these viral proteins to block cGAS-STING signaling,
c-di-GMP induced an IFN- response in the cGAS-STING cells that was not inhibited by
any of the IFN antagonists (Fig. 7F). Finally, as was previously seen with EBOV VP35, the
presence of an ATM inhibitor reduced but did not eliminate the doxorubicin-induced
IFN response in cGAS-STING cells, and this residual activity was not suppressed by the
transfected viral proteins (Fig. 7C to F). These data suggest that activators of the ATM
and cGAS-STING pathways might be exploited as a general strategy to induce an
antiviral state in cells infected by negative-sense RNA viruses.
DISCUSSION
DNA damage responses can trigger innate immune responses (22, 38, 52). Doxoru-
bicin is a widely used anticancer drug that induces DNA damage (42). Its ability to
intercalate with DNA, inhibit type II topoisomerase, generate free oxygen radicals, and
trigger the DNA damage response contributes to its cytotoxic and cytostatic effects
(33). In addition, doxorubicin modulates immune and cytokine responses that may
inﬂuence its anticancer effects. For example, activation of IFN--induced Jak-STAT
signaling and ISG induction contributes to its antitumor effects (23). However, the
molecular basis by which doxorubicin triggers immune modulation has not been
clearly elucidated.
Because VP35 IFN inhibition is critical for EBOV virulence, we established a novel HTS
assay that would allow the identiﬁcation of compounds that activate the IFN- pro-
moter in the presence or absence of VP35. A screen performed with the assay identiﬁed
doxorubicin, daunorubicin, and other anthracyclines as reproducible inducers of IFN in
the presence of VP35 and SeV infection. Because the compounds were subsequently
found to induce an IFN response in the absence of SeV infection and in the absence or
presence of VP35, it was concluded that they do not directly inhibit VP35 and that the
IFN induction pathway that is activated bypasses the inhibitory effects of VP35. VP35
has been well characterized as an inhibitor of the RIG-I signaling pathway that responds
to 5=-triphosphate RNAs, short dsRNAs, and other RNA species to induce IFN expression.
Data also suggest that VP35 can inhibit signaling via a second RIG-I-like receptor, MDA5.
Mechanisms of RLR pathway inhibition by VP35 include sequestration of RIG-I-
activating dsRNAs by the C-terminal dsRNA binding domain of VP35, known as the
interferon inhibitory domain (IID), and interaction of the IID with host protein PACT, a
facilitator of RIG-I activation (11, 75–77). Additional mechanisms include interaction
with the kinases TBK1 and IB kinase  (IKK), resulting in inhibition of IRF-3 phosphor-
ylation, and facilitation of IRF-7 SUMOylation to repress IFN gene transcription (78, 79).
Induction of IFN responses by anthracyclines in the presence or absence of VP35
suggests that a non-RLR signaling pathway was activated.
Although doxorubicin and other compounds that cause DNA damage had previ-
ously been implicated as IFN inducers, proposed mechanisms differ between studies
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(21, 38, 67). One study implicated signaling through ATM, a serine/threonine kinase that
phosphorylates numerous substrates and mediates signaling downstream of the DNA
break to facilitate DNA repair. The results of our screen are consistent with the known
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FIG 7 Doxorubicin bypasses multiple RNA virus IFN antagonists. IFN- promoter (A) or ISG54 promoter (B) ﬁreﬂy luciferase
reporter gene assays were performed. The empty vector (vector) or expression plasmids for the indicated viral IFN
antagonists were transfected. The next day, cells were mock treated, treated with doxorubicin, or infected with SeV.
Eighteen hours later, luciferase activity was determined. Fold induction was determined by setting the mock-treated
(medium  DMSO) empty-vector controls to 1. Error bars indicate standard deviations from three independent replicates.
Experiments similar to those described for panels A and B were performed to detect IFN- promoter (C) or ISG54 promoter
(D) reporter gene activity but with ATM kinase inhibitor pretreatment. An experiment similar to that described for panel
C was performed using either the control-FF cells (E) or the cGAS-wt-STING-FF stable IFN- reporter cells described in the
legend to Fig. 5B (F). Data represent means  standard deviations and are representative of three independent
experiments. Error bars indicate standard deviations from three independent replicates. **, P value  0.01; ***, P value 
0.001; ****, P value  0.0001 (one-way analysis of variance followed by Tukey’s test). See also Fig. S4 in the supplemental
material.
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response and to activate ATM, as they triggered the phosphorylation of ATM and its
downstream target p53 on serine 15 (21). Further, activation of the IFN response by
doxorubicin and daunorubicin was impaired by either of two inhibitors of the DNA
damage response signaling pathway, ATM inhibitor Ku55933, which directly inhibits
ATM, or mirin, which inhibits the Mre11-Rad50-Nbs1 (MRN)-ATM pathway. Doxorubicin
induces dsDNA breaks by targeting topoisomerase 2 (Top2), leading to stabilized
cleavable dsDNA breaks to which the enzyme is covalently bound. Downregulation of
Top2A has previously been demonstrated to reduce doxorubicin-mediated cytotoxicity
(34). Consistent with inhibition of Top2A as a trigger for the ATM-dependent IFN
response, knockdown of Top2A in our cell lines that lack detectable cGAS and STING
decreased the IFN response triggered by doxorubicin.
Because the cGAS-STING DNA-sensing pathway has been implicated in responding
to DNA damage (22), we also investigated whether cGAS and STING can be activated
by doxorubicin. When cGAS and STING were present, doxorubicin also triggered an IFN
response by this pathway. cGAS recognizes cytosolic DNA derived from either patho-
gens or damaged host cells and induces an IFN response through the adaptor protein
STING. cGAS binds DNA and catalyzes the synthesis of cGAMP. cGAMP, an endogenous
second messenger, binds and activates signaling through STING (27, 28). According to
published studies and our Western blotting data, 293T cells lack detectable cGAS or
STING expression. We therefore stably introduced STING or both cGAS and STING into
the reporter cell lines. The presence of cGAS and STING resulted in enhanced IFN
responses to doxorubicin. The enhancement required the presence of STING and a form
of cGAS able to recognize DNA and generate CDN, indicating that doxorubicin activates
the DNA-sensing pathway to trigger IFN responses. In the cGAS- and STING-expressing
cells, the ATM pathway still contributes to the response to doxorubicin as evidenced by
the reduced IFN response in the presence of ATM inhibitor. Whether ATM and cGAS-
STING act as separate pathways in which each induces the IFN- response or whether
they act within the same pathway remains to be determined.
Cytoplasmic DNA triggers activation of the cGAS-STING pathway, so we evaluated if
doxorubicin can induce production of cytoplasmic DNA. In our experiments, we
detected increased abundance of ssDNA upon doxorubicin treatment that also colo-
calized with cGAS, implicating cGAS in IFN induction by doxorubicin. To further support
the idea that accumulation of DNA is responsible for IFN induction by doxorubicin in
the presence of cGAS-STING, we performed studies with Trex1. Trex1 is a 3=-5= exonu-
clease responsible for degrading cytoplasmic DNA. Mutations in Trex1 cause the
IFN-associated autoimmune disease Aicardi-Goutières syndrome (AGS) (80). Because
IFN induction was abolished in the cGAS-STING cells when Trex1 was overexpressed,
doxorubicin likely results in the accumulation of cytoplasmic ssDNA that activates
cGAS-STING signaling to induce IFN production. Furthermore, we also noticed that in
the absence of cGAS-STING, Trex1 overexpression has little or no effect on IFN activa-
tion, suggesting that doxorubicin-mediated IFN activation by the ATM pathway is not
entirely dependent on cytoplasmic DNA production. dsDNA could also contribute to
the observed IFN induction by doxorubicin via cGAS-STING, as we did not include or
exclude its presence. Overall, our results indicate roles for both cGAS-STING and ATM
in IFN induction by doxorubicin, a response that is not blocked by VP35 (Fig. 8). These
data suggest that the ATM and cGAS-STING DNA-sensing pathways have potential as
therapeutic approaches for EBOV because they bypass the inhibitory effects of VP35.
It has been demonstrated that activation of RLR pathways prior to EBOV infection
can substantially suppress EBOV replication in cell culture (81). Further, recombinant
EBOVs with mutant VP35s defective for dsRNA binding and RLR inhibition are highly
attenuated in cell types that can mount an IFN response and in in vivo models of
infection (12, 17, 82). Therefore, activation of IFN-inducing pathways that bypass VP35
inhibitory functions would also be expected to elicit an IFN response that can impair
virus replication. Consistent with this, doxorubicin decreases EBOV growth in A549 cells
at noncytotoxic concentrations. Induction of antiviral ISGs likely explains this suppres-
sion of EBOV growth. As shown in Fig. S2A in the supplemental material, cGAS and
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STING were not detected by Western blotting in A549 cells. Therefore, it is unclear to
what extent cGAS-STING may contribute to the antiviral effects of doxorubicin in these
cells. It is possible that cells with more robust cGAS-STING levels would demonstrate a
more profound inhibition. In vivo, macrophages and dendritic cells are the primary
target for EBOV infection (83, 84). These cell types also express cGAS and STING (85, 86),
and our dendritic cell data (Fig. S2E and F) demonstrate the responsiveness of these
cells to doxorubicin. Therefore, it seems likely that the in vivo cellular targets of EBOV
will be responsive to this therapeutic approach.
Previous studies have demonstrated several mechanisms by which VP35 can impair
activation of RLR signaling by RNA and RNA virus-triggered IFN production (8–11, 14).
Inhibition correlates with VP35 dsRNA binding activity and VP35 interaction with host
protein PACT, which facilitates activation of RIG-I by dsRNA or by virus infection (11, 75,
77). Studies in primary human dendritic cells (DCs) support these activities of VP35 in
biologically relevant cell types and suggest inhibition of both RIG-I and the related
RIG-I-like pattern recognition sensor MDA5 (87). In DCs, VP35 not only blocks IFN
production but also decreases cytokine and chemokine production, inhibits upregula-
tion of costimulatory markers, and impairs activation of T cells in response to virus
infection (15). Therefore, activation of IFN responses via non-RLR pattern recognition
receptors in EBOV-infected DCs might also promote activation of adaptive immune
responses to EBOV. However, VP35 is also reported to impair activation of IRF-3 and























FIG 8 Proposed model for activation of IFN by doxorubicin bypassing IFN antagonism by Ebola virus VP35 protein. Ebola virus VP35
antagonizes IFN responses triggered by RIG-I-like receptors (RLR), which include RIG-I and melanoma differentiation-associated protein
5 (MDA5). RLR detect cytoplasmic double-stranded RNAs (dsRNAs) or RNAs with 5= triphosphate (5= pppdsRNA), products of RNA virus
replication. The activation of RLR is further facilitated by protein kinase R activator (PACT). Upon activation, RLR signal through the
mitochondrial antiviral signaling protein (MAVS) to activate kinases IB kinase  (IKK) and TBK1. These kinases phosphorylate IFN
regulatory factor 3 (IRF-3) or IRF-7, which then accumulates in the nucleus and promotes expression of type I IFNs. Doxorubicin
treatment results in IFN induction by two independent pathways: the DNA damage repair response pathway involving ATM and DNA
sensor machinery cGAS-STING. The DNA damage leads to activation of ATM that triggers activation of an IRF-3 and/or NF-B response,
thus leading to IFN activation. Furthermore, damaged DNA can also be detected by a cytoplasmic DNA sensor, cGAS, which through
the STING–TBK1–IRF-3 axis leads to activation of IFN responses. Interestingly, these DNA-mediated IFN activation pathways are not
subverted by the presence of Ebola virus VP35 protein. Thus, these data suggest novel avenues for developing antiviral therapeutics.
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effects on SUMOylation machinery (79). Therefore, why does it not still prevent induc-
tion of IFN responses by the ATM and cGAS-STING pathways? We hypothesize that
inhibition at these downstream steps is relatively weak and can be overcome by
relatively strong IFN-inducing signals. Consistent with this, in DCs, the relatively weak
IFN response of cells to lipopolysaccharide (LPS) was impaired by wild-type or mu-
tant VP35 (15). However, only wild-type VP35 could effectively impair the robust IFN
response induced by SeV infection. This would also explain why mutations that
abrogate VP35 dsRNA binding activity and inhibition of RLR activation but which do not
impair VP35 inhibition of signaling by TBK1 and IKK are sufﬁcient to lead to severe
attenuation of EBOV in cells and in vivo.
Given our data in the VP35-expressing cells, we hypothesized that the ATM and
cGAS-STING pathways may provide a means to generally trigger antiviral responses in
cells infected with negative-sense RNA viruses. Such viruses are well documented to
encode inhibitors of RLR signaling and many also encode inhibitors of IFN-/-induced
Jak-STAT signaling. However, such viruses may not have evolved mechanisms to
counter DNA-triggered innate immune signaling pathways. The activation of such
pathways may have multiple beneﬁcial effects, such as inducing IFN and also triggering
an intrinsic, IFN-independent antiviral response, for example, by activation of IRF-3,
which can trigger antiviral gene expression independently of IFN production (38, 88,
89). Consistent with our hypothesis, doxorubicin induced an IFN response in the
presence of IFN-antagonist proteins from Marburg virus, inﬂuenza A virus, Nipah virus,
and respiratory syncytial virus. Thus, the data in this study suggest the ATM and
cGAS-STING pathways as novel avenues to develop new broad-spectrum antivirals.
MATERIALS AND METHODS
Cell lines. 293T and A549 cells were obtained from the American Type Culture Collection (ATCC)
(http://www.atcc.org) and maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco) supple-
mented with 10% fetal bovine serum (FBS; HyClone) and penicillin-streptomycin (Gibco). Human healthy
ﬁbroblasts (GM05294; Coriell Institute for Medical Research) and AT patient ﬁbroblasts (GM02052; Coriell
Institute for Medical Research) were maintained in DMEM containing 10% (vol/vol) fetal calf serum (FCS;
HyClone). Human monocyte-derived dendritic cells (MDDCs) were generated from CD14 cells puriﬁed
from concentrated leukocytes of healthy human donors (New York Blood Center), as described previously
(15). For additional information on cell lines, please see the supplemental material.
HTS. High-throughput screening (HTS) was performed at the Mount Sinai Integrated Screening Core.
To evaluate the robustness of the assay, we calculated the Z factor (27) and signal-to-background (S/B)
ratio.
Luciferase reporter gene assays. HEK293T cells were transfected by using Lipofectamine 2000
(Invitrogen) with the indicated expression plasmids along with the reporter plasmids. At 20 h posttrans-
fection, the cell lysates were assayed with the dual luciferase reporter assay (Promega), and ﬁreﬂy
luciferase activity was normalized to Renilla luciferase activity.
Monitoring cellular interferon responses. To monitor activation of IFN responses, cells were either
treated with doxorubicin (1 M or 3 M) or TNF- (20 ng) or transfected with c-di-GMP (20 g/ml) using
LyoVec (InvivoGen) for the indicated times. SeV (Cantell strain) stocks were prepared by growth in
10-day-old embryonated chicken eggs for 2 days at 37°C, and infections were performed as described in
Results.
RNA extraction and qRT-PCR for cellular mRNAs. The total RNA was isolated from the cells using
Trizol according to the manufacturer’s instructions. cDNAs were synthesized using the SuperScript III
First-Strand synthesis system (Invitrogen). The resulting cDNAs were used as the templates for subse-
quent quantitative PCRs using gene-speciﬁc primers (IFN-, ISG54, IFN-, or -actin).
EBOV-GFP infection assays. All experiments using infectious EBOV were performed in biosafety
level 4 (BSL-4) facilities of the Galveston National Laboratory. The viral titers were determined by plaque
assay. The cell viability in infection experiments was determined using the Viral ToxGlo assay (Promega),
and ATP content was determined by reading luminescence using a BioTek Synergy HT plate reader.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00368-17.
TEXT S1, DOCX ﬁle, 0.1 MB.
FIG S1, EPS ﬁle, 3.3 MB.
FIG S2, EPS ﬁle, 2.5 MB.
FIG S3, PDF ﬁle, 0.4 MB.
FIG S4, EPS ﬁle, 2.8 MB.
Luthra et al. ®
















The authors were supported by U.S. National Institutes of Health (NIH) grants U19
AI109664 (Basler, principal investigator) to C.F.B., N.S.W., and A.B.; R01 AI107056 to
D.W.L.; and R01 AI073450 to A.F.-S. The authors were also supported by Department of
Defense (DoD) grants DARPA HR0011-11-C-0094 (Profecy, principal investigator) to
A.F.-S.
P.L. and C.F.B. designed the research; P.L., S.A., B.C.Y., C.A.P., B.T., L.K.M., N.S.W., and
A.B. performed the research; P.L., B.C.Y., C.A.P., B.T., L.K.M., N.S.W., A.B., and C.F.B.
analyzed the data; P.L., S.A., B.C.Y., D.W.L., and A.F.-S. generated reagents, including
plasmids and cell lines for this study; and P.L. and C.F.B. wrote the paper.
REFERENCES
1. Mahanty S, Bray M. 2004. Pathogenesis of ﬁloviral haemorrhagic fevers.
Lancet Infect Dis 4:487– 498. https://doi.org/10.1016/S1473-3099
(04)01103-X.
2. Wong G, Qiu X, Olinger GG, Kobinger GP. 2014. Post-exposure therapy of
ﬁlovirus infections. Trends Microbiol 22:456–463. https://doi.org/10
.1016/j.tim.2014.04.002.
3. Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. 2010. Ebolavirus
VP24 binding to karyopherins is required for inhibition of interferon
signaling. J Virol 84:1169–1175. https://doi.org/10.1128/JVI.01372-09.
4. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C,
Volchkov VE, Nichol ST, Basler CF. 2006. Ebola virus VP24 binds
karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol
80:5156–5167. https://doi.org/10.1128/JVI.02349-05.
5. Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. 2007. Ebola virus
VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin
alpha proteins with activated STAT1. J Virol 81:13469–13477. https://doi
.org/10.1128/JVI.01097-07.
6. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN,
Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe
GK. 2014. Ebola virus VP24 targets a unique NLS binding site on
karyopherin alpha 5 to selectively compete with nuclear import of
phosphorylated STAT1. Cell Host Microbe 16:187–200. https://doi.org/
10.1016/j.chom.2014.07.008.
7. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherin-
mediated restriction of ﬁlovirus budding is antagonized by the Ebola
glycoprotein. Proc Natl Acad Sci U S A 106:2886–2891. https://doi.org/
10.1073/pnas.0811014106.
8. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E,
Bray M, Klenk HD, Palese P, García-Sastre A. 2003. The Ebola virus VP35
protein inhibits activation of interferon regulatory factor 3. J Virol 77:
7945–7956. https://doi.org/10.1128/JVI.77.14.7945-7956.2003.
9. Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD,
García-Sastre A, Palese P. 2000. The Ebola virus VP35 protein functions as
a type I IFN antagonist. Proc Natl Acad Sci U S A 97:12289–12294.
https://doi.org/10.1073/pnas.220398297.
10. Hartman AL, Towner JS, Nichol STA. 2004. A C-terminal basic amino acid
motif of Zaire ebolavirus VP35 is essential for type I interferon antago-
nism and displays high identity with the RNA-binding domain of another
interferon antagonist, the NS1 protein of inﬂuenza A virus. Virology
328:177–184. https://doi.org/10.1016/j.virol.2004.07.006.
11. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan
P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amaras-
inghe GK. 2010. Structural basis for dsRNA recognition and interferon
antagonism by Ebola VP35. Nat Struct Mol Biol 17:165–172. https://doi
.org/10.1038/nsmb.1765.
12. Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP,
Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF.
2010. Mutations abrogating VP35 interaction with double-stranded RNA
render Ebola virus avirulent in guinea pigs. J Virol 84:3004–3015. https://
doi.org/10.1128/JVI.02459-09.
13. Schümann M, Gantke T, Mühlberger E. 2009. Ebola virus VP35 antago-
nizes PKR activity through its C-terminal interferon inhibitory domain. J
Virol 83:8993–8997. https://doi.org/10.1128/JVI.00523-09.
14. Cárdenas WB, Loo YM, Gale M, Hartman AL, Kimberlin CR, Martínez-
Sobrido L, Saphire EO, Basler CF. 2006. Ebola virus VP35 protein binds
double-stranded RNA and inhibits alpha/beta interferon production
induced by RIG-I signaling. J Virol 80:5168–5178. https://doi.org/10
.1128/JVI.02199-05.
15. Yen B, Mulder LC, Martinez O, Basler CF. 2014. Molecular basis for
ebolavirus VP35 suppression of human dendritic cell maturation. J Virol
88:12500–12510. https://doi.org/10.1128/JVI.02163-14.
16. Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA,
Bukreyev A. 2013. The lack of maturation of Ebola virus-infected den-
dritic cells results from the cooperative effect of at least two viral
domains. J Virol 87:7471–7485. https://doi.org/10.1128/JVI.03316-12.
17. Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST.
2008. Inhibition of IRF-3 activation by VP35 is critical for the high level
of virulence of Ebola virus. J Virol 82:2699–2704. https://doi.org/10.1128/
JVI.02344-07.
18. Hartman AL, Dover JE, Towner JS, Nichol ST. 2006. Reverse genetic
generation of recombinant Zaire Ebola viruses containing disrupted
IRF-3 inhibitory domains results in attenuated virus growth in vitro and
higher levels of IRF-3 activation without inhibiting viral transcription or
replication. J Virol 80:6430–6440. https://doi.org/10.1128/JVI.00044-06.
19. Chan YK, Gack MU. 2016. Viral evasion of intracellular DNA and RNA
sensing. Nat Rev Microbiol 14:360–373. https://doi.org/10.1038/nrmicro
.2016.45.
20. Kell AM, Gale M, Jr. 2015. RIG-I in RNA virus recognition. Virology
479-480:110–121. https://doi.org/10.1016/j.virol.2015.02.017.
21. Brzostek-Racine S, Gordon C, Van Scoy S, Reich NC. 2011. The DNA
damage response induces IFN. J Immunol 187:5336–5345. https://doi
.org/10.4049/jimmunol.1100040.
22. Härtlova A, Erttmann SF, Rafﬁ FA, Schmalz AM, Resch U, Anugula S,
Lienenklaus S, Nilsson LM, Kröger A, Nilsson JA, Ek T, Weiss S, Gekara NO.
2015. DNA damage primes the type I interferon system via the cytosolic
DNA sensor STING to promote anti-microbial innate immunity. Immunity
42:332–343. https://doi.org/10.1016/j.immuni.2015.01.012.
23. Hussner J, Ameling S, Hammer E, Herzog S, Steil L, Schwebe M, Niessen
J, Schroeder HW, Kroemer HK, Ritter CA, Völker U, Bien S. 2012. Regu-
lation of interferon-inducible proteins by doxorubicin via interferon
gamma-Janus tyrosine kinase-signal transducer and activator of tran-
scription signaling in tumor cells. Mol Pharmacol 81:679–688. https://
doi.org/10.1124/mol.111.075994.
24. Kurz EU, Douglas P, Lees-Miller SP. 2004. Doxorubicin activates ATM-
dependent phosphorylation of multiple downstream targets in part
through the generation of reactive oxygen species. J Biol Chem 279:
53272–53281. https://doi.org/10.1074/jbc.M406879200.
25. Kurz EU, Lees-Miller SP. 2004. DNA damage-induced activation of ATM
and ATM-dependent signaling pathways. DNA Repair (Amst) 3:889–900.
https://doi.org/10.1016/j.dnarep.2004.03.029.
26. Li N, Banin S, Ouyang H, Li GC, Courtois G, Shiloh Y, Karin M, Rotman G.
2001. ATM is required for IkappaB kinase (IKKk) activation in response to
DNA double strand breaks. J Biol Chem 276:8898–8903. https://doi.org/
10.1074/jbc.M009809200.
27. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is
a cytosolic DNA sensor that activates the type I interferon pathway.
Science 339:786–791. https://doi.org/10.1126/science.1232458.
28. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP
is an endogenous second messenger in innate immune signaling by
cytosolic DNA. Science 339:826–830. https://doi.org/10.1126/science
.1229963.
29. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M,
Hayakawa Y, Hammond MC, Vance RE. 2013. The innate immune DNA
Topoisomerase II Inhibitors Induce IFN Responses ®















sensor cGAS produces a noncanonical cyclic dinucleotide that activates
human STING. Cell Rep 3:1355–1361. https://doi.org/10.1016/j.celrep
.2013.05.009.
30. Ishikawa H, Barber GN. 2008. STING is an endoplasmic reticulum adaptor
that facilitates innate immune signalling. Nature 455:674–678. https://
doi.org/10.1038/nature07317.
31. Ishikawa H, Ma Z, Barber GN. 2009. STING regulates intracellular DNA-
mediated, type I interferon-dependent innate immunity. Nature 461:
788–792. https://doi.org/10.1038/nature08476.
32. Liu H, Wang H, Xiang D, Guo W. 2016. Pharmaceutical measures to
prevent doxorubicin-induced cardiotoxicity. Mini Rev Med Chem 17:
44–50. https://doi.org/10.2174/1389557516666160621083659.
33. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum
S, Silber R, Potmesil M. 1989. DNA topoisomerase II-mediated interaction
of doxorubicin and daunorubicin congeners with DNA. Cancer Res
49:5969–5978.
34. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ,
Lowe SW, Hemann MT. 2008. Topoisomerase levels determine chemo-
therapy response in vitro and in vivo. Proc Natl Acad Sci U S A 105:
9053–9058. https://doi.org/10.1073/pnas.0803513105.
35. Bracci L, Schiavoni G, Sistigu A, Belardelli F. 2014. Immune-based mech-
anisms of cytotoxic chemotherapy: implications for the design of novel
and rationale-based combined treatments against cancer. Cell Death
Differ 21:15–25. https://doi.org/10.1038/cdd.2013.67.
36. Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N,
Datta S, Koller JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ,
Sexl V, Villunger A, Doppler W. 2013. Lapatinib and doxorubicin enhance
the Stat1-dependent antitumor immune response. Eur J Immunol 43:
2718–2729. https://doi.org/10.1002/eji.201242505.
37. Fortune JM, Osheroff N. 2000. Topoisomerase II as a target for anticancer
drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol
64:221–253. https://doi.org/10.1016/S0079-6603(00)64006-0.
38. Kim T, Kim TY, Song YH, Min IM, Yim J, Kim TK. 1999. Activation of
interferon regulatory factor 3 in response to DNA-damaging agents. J
Biol Chem 274:30686–30689. https://doi.org/10.1074/jbc.274.43.30686.
39. Wheeler HR, Geczy CL. 1990. Induction of macrophage procoagulant
expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer
46:626–632. https://doi.org/10.1002/ijc.2910460413.
40. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter
for use in evaluation and validation of high throughput screening
assays. J Biomol Screen 4:67–73. https://doi.org/10.1177/1087057
19900400206.
41. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V,
Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I.
2010. Postexposure protection of non-human primates against a lethal
Ebola virus challenge with RNA interference: a proof-of-concept study.
Lancet 375:1896–1905. https://doi.org/10.1016/S0140-6736(10)60357-1.
42. Aubel-Sadron G, Londos-Gagliardi D. 1984. Daunorubicin and doxorubi-
cin, anthracycline antibiotics, a physicochemical and biological review.
Biochimie 66:333–352. https://doi.org/10.1016/0300-9084(84)90018-X.
43. Strelitz F, Flon H, Weiss U, Asheshov IN. 1956. Aklavin, an antibiotic
substance with antiphage activity. J Bacteriol 72:90–94.
44. René B, Fossé P, Khélifa T, Jacquemin-Sablon A, Bailly C. 1997. Cytotox-
icity and interaction of amsacrine derivatives with topoisomerase II: role
of the 1= substitute on the aniline nucleus. Bull Cancer 84:941–948. (In
French.)
45. Vock EH, Lutz WK, Hormes P, Hoffmann HD, Vamvakas S. 1998. Discrim-
ination between genotoxicity and cytotoxicity in the induction of DNA
double-strand breaks in cells treated with etoposide, melphalan, cispla-
tin, potassium cyanide, Triton X-100, and gamma-irradiation. Mutat Res
413:83–94. https://doi.org/10.1016/S1383-5718(98)00019-9.
46. Lavin MF. 2008. Ataxia-telangiectasia: from a rare disorder to a paradigm
for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759–769. https://
doi.org/10.1038/nrm2514.
47. Lavin MF, Shiloh Y. 1997. The genetic defect in ataxia-telangiectasia.
Annu Rev Immunol 15:177–202. https://doi.org/10.1146/annurev
.immunol.15.1.177.
48. Shiloh Y. 2006. The ATM-mediated DNA-damage response: taking shape.
Trends Biochem Sci 31:402–410. https://doi.org/10.1016/j.tibs.2006.05
.004.
49. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. 2002. Regulation of the
IRF-1 tumour modiﬁer during the response to genotoxic stress involves an
ATM-dependent signalling pathway. Oncogene 21:7776–7785. https://doi
.org/10.1038/sj.onc.1205981.
50. Ferguson BJ, Mansur DS, Peters NE, Ren H, Smith GL. 2012. DNA-PK is a
DNA sensor for IRF-3-dependent innate immunity. Elife 1:e00047.
https://doi.org/10.7554/eLife.00047.
51. Zhang X, Brann TW, Zhou M, Yang J, Oguariri RM, Lidie KB, Imamichi H,
Huang DW, Lempicki RA, Baseler MW, Veenstra TD, Young HA, Lane HC,
Imamichi T. 2011. Cutting edge: Ku70 is a novel cytosolic DNA sensor
that induces type III rather than type I IFN. J Immunol 186:4541–4545.
https://doi.org/10.4049/jimmunol.1003389.
52. Gasser S, Raulet DH. 2006. The DNA damage response arouses the
immune system. Cancer Res 66:3959–3962. https://doi.org/10.1158/
0008-5472.CAN-05-4603.
53. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM,
Jackson SP, Curtin NJ, Smith GC. 2004. Identiﬁcation and characteriza-
tion of a novel and speciﬁc inhibitor of the ataxia-telangiectasia mutated
kinase ATM. Cancer Res 64:9152–9159. https://doi.org/10.1158/0008
-5472.CAN-04-2727.
54. Dupré A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML,
Kopelovich L, Jasin M, Baer R, Paull TT, Gautier J. 2008. A forward chemical
genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat
Chem Biol 4:119–125. https://doi.org/10.1038/nchembio.63.
55. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT,
Roninson IB. 1993. Isolation of genetic suppressor elements, inducing
resistance to topoisomerase II-interactive cytotoxic drugs, from human
topoisomerase II cDNA. Proc Natl Acad Sci U S A 90:3231–3235. https://
doi.org/10.1073/pnas.90.8.3231.
56. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F, Ludwig H,
Sutter G, Suzuki K, Hemmi H, Sato S, Yamamoto M, Uematsu S, Kawai T,
Takeuchi O, Akira S. 2006. A toll-like receptor-independent antiviral
response induced by double-stranded B-form DNA. Nat Immunol
7:40–48. https://doi.org/10.1038/ni1282.
57. Stetson DB, Medzhitov R. 2006. Recognition of cytosolic DNA activates
an IRF3-dependent innate immune response. Immunity 24:93–103.
https://doi.org/10.1016/j.immuni.2005.12.003.
58. Ablasser A, Hornung V. 2013. DNA sensing unchained. Cell Res 23:
585–587. https://doi.org/10.1038/cr.2013.28.
59. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, Hopfner KP,
Ludwig J, Hornung V. 2013. cGAS produces a 2=-5=-linked cyclic dinu-
cleotide second messenger that activates STING. Nature 498:380–384.
https://doi.org/10.1038/nature12306.
60. Abe T, Barber GN. 2014. Cytosolic-DNA-mediated, STING-dependent proin-
ﬂammatory gene induction necessitates canonical NF-B activation
through TBK1. J Virol 88:5328–5341. https://doi.org/10.1128/JVI.00037-14.
61. Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ. 2013. Cyclic
GMP-AMP containing mixed phosphodiester linkages is an endogenous
high-afﬁnity ligand for STING. Mol Cell 51:226–235. https://doi.org/10
.1016/j.molcel.2013.05.022.
62. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M,
Hayakawa Y, Vance RE. 2011. STING is a direct innate immune sensor of
cyclic di-GMP. Nature 478:515–518. https://doi.org/10.1038/nature10429.
63. Diner EJ, Vance RE. 2014. Taking the STING out of cytosolic DNA sensing.
Trends Immunol 35:1–2. https://doi.org/10.1016/j.it.2013.10.011.
64. Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G,
Hornung V, Hopfner KP. 2013. Structural mechanism of cytosolic DNA
sensing by cGAS. Nature 498:332–337. https://doi.org/10.1038/
nature12305.
65. Kranzusch PJ, Lee AS, Berger JM, Doudna JA. 2013. Structure of human
cGAS reveals a conserved family of second-messenger enzymes in in-
nate immunity. Cell Rep 3:1362–1368. https://doi.org/10.1016/j.celrep
.2013.05.008.
66. Kranzusch PJ, Vance RE. 2013. cGAS dimerization entangles DNA recog-
nition. Immunity 39:992–994. https://doi.org/10.1016/j.immuni.2013.11
.012.
67. Deng X, Ljunggren-Rose A, Maas K, Sriram S. 2005. Defective ATM-p53-
mediated apoptotic pathway in multiple sclerosis. Ann Neurol 58:
577–584. https://doi.org/10.1002/ana.20600.
68. Westbrook AM, Schiestl RH. 2010. Atm-deﬁcient mice exhibit increased
sensitivity to dextran sulfate sodium-induced colitis characterized by
elevated DNA damage and persistent immune activation. Cancer Res
70:1875–1884. https://doi.org/10.1158/0008-5472.CAN-09-2584.
69. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara
S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. 2006.
Deﬁciency in the repair of DNA damage by homologous recombination
and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res
66:8109–8115. https://doi.org/10.1158/0008-5472.CAN-06-0140.
Luthra et al. ®















70. Lahaye X, Manel N. 2014. HIV-2 reveals an antiviral mechanism of
detection by innate immunity. Med Sci (Paris) 30:610–613. https://doi
.org/10.1051/medsci/20143006004.
71. Yang YG, Lindahl T, Barnes DE. 2007. Trex1 exonuclease degrades ssDNA
to prevent chronic checkpoint activation and autoimmune disease. Cell
131:873–886. https://doi.org/10.1016/j.cell.2007.10.017.
72. Gall A, Treuting P, Elkon KB, Loo YM, Gale M, Barber GN, Stetson DB.
2012. Autoimmunity initiates in nonhematopoietic cells and progresses
via lymphocytes in an interferon-dependent autoimmune disease. Im-
munity 36:120–131. https://doi.org/10.1016/j.immuni.2011.11.018.
73. Fye JM, Orebaugh CD, Cofﬁn SR, Hollis T, Perrino FW. 2011. Dominant
mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres
syndrome. J Biol Chem 286:32373–32382. https://doi.org/10.1074/jbc
.M111.276287.
74. Grieves JL, Fye JM, Harvey S, Grayson JM, Hollis T, Perrino FW. 2015.
Exonuclease TREX1 degrades double-stranded DNA to prevent sponta-
neous lupus-like inﬂammatory disease. Proc Natl Acad Sci U S A 112:
5117–5122. https://doi.org/10.1073/pnas.1423804112.
75. Bale S, Julien JP, Bornholdt ZA, Krois AS, Wilson IA, Saphire EO. 2013.
Ebolavirus VP35 coats the backbone of double-stranded RNA for inter-
feron antagonism. J Virol 87:10385–10388. https://doi.org/10.1128/JVI
.01452-13.
76. Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Ama-
rasinghe GK. 2009. Structure of the Ebola VP35 interferon inhibitory
domain. Proc Natl Acad Sci U S A 106:411–416. https://doi.org/10.1073/
pnas.0807854106.
77. Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, Liu G, Leung
DW, Geisbert TW, Ebihara H, Amarasinghe GK, Basler CF. 2013. Mutual
antagonism between the Ebola virus VP35 protein and the RIG-I activa-
tor PACT determines infection outcome. Cell Host Microbe 14:74–84.
https://doi.org/10.1016/j.chom.2013.06.010.
78. Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M, Ozato K.
2009. Ebola Zaire virus blocks type I interferon production by exploiting
the host SUMO modiﬁcation machinery. PLoS Pathog 5:e1000493.
https://doi.org/10.1371/journal.ppat.1000493.
79. Prins KC, Cárdenas WB, Basler CF. 2009. Ebola virus protein VP35 impairs
the function of interferon regulatory factor-activating kinases IKKepsilon
and TBK-1. J Virol 83:3069–3077. https://doi.org/10.1128/JVI.01875-08.
80. Crow YJ, Rehwinkel J. 2009. Aicardi-Goutieres syndrome and related
phenotypes: linking nucleic acid metabolism with autoimmunity. Hum
Mol Genet 18:R130–R136. https://doi.org/10.1093/hmg/ddp293.
81. Spiropoulou CF, Ranjan P, Pearce MB, Sealy TK, Albariño CG, Gangappa
S, Fujita T, Rollin PE, Nichol ST, Ksiazek TG, Sambhara S. 2009. RIG-I
activation inhibits ebolavirus replication. Virology 392:11–15. https://doi
.org/10.1016/j.virol.2009.06.032.
82. Hartman AL, Ling L, Nichol ST, Hibberd ML. 2008. Whole-genome ex-
pression proﬁling reveals that inhibition of host innate immune re-
sponse pathways by Ebola virus can be reversed by a single amino acid
change in the VP35 protein. J Virol 82:5348–5358. https://doi.org/10
.1128/JVI.00215-08.
83. Bray M. 2005. Pathogenesis of viral hemorrhagic fever. Curr Opin Immu-
nol 17:399–403. https://doi.org/10.1016/j.coi.2005.05.001.
84. Bray M, Geisbert TW. 2005. Ebola virus: the role of macrophages and
dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J
Biochem Cell Biol 37:1560–1566. https://doi.org/10.1016/j.biocel.2005
.02.018.
85. Cai X, Chiu YH, Chen ZJ. 2014. The cGAS-cGAMP-STING pathway of
cytosolic DNA sensing and signaling. Mol Cell 54:289–296. https://doi
.org/10.1016/j.molcel.2014.03.040.
86. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. 2013. Pivotal roles of
cGAS-cGAMP signaling in antiviral defense and immune adjuvant ef-
fects. Science 341:1390–1394. https://doi.org/10.1126/science.1244040.
87. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M,
Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A,
Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R,
Bowie AG, Bennett KL, Colinge J, Superti-Furga G. 2012. Viral immune
modulators perturb the humanmolecular network by common and unique
strategies. Nature 487:486–490. https://doi.org/10.1038/nature11289.
88. Tanaka Y, Chen ZJ. 2012. STING speciﬁes IRF3 phosphorylation by TBK1
in the cytosolic DNA signaling pathway. Sci Signal 5:ra20. https://doi
.org/10.1126/scisignal.2002521.
89. Nakhaei P, Hiscott J, Lin R. 2010. STING-ing the antiviral pathway. J Mol
Cell Biol 2:110–112. https://doi.org/10.1093/jmcb/mjp048.
Topoisomerase II Inhibitors Induce IFN Responses ®







 April 13, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
